Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Type 1 diabetes
Biotech
Vertex drops cell-device diabetes combo over poor ph. 1 results
Vertex is ending one of its two islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production.
James Waldron
Mar 31, 2025 4:20am
Insulet Type 1 study shows gains in switch to auto insulin pump
Mar 20, 2025 12:12pm
Sana stock price triples after allogeneic cell therapy data drop
Jan 8, 2025 10:38am
Lilly posts more positive data on once-weekly insulin prospect
Sep 11, 2024 2:05pm
FDA OKs artificial pancreas app for pregnant women with diabetes
May 28, 2024 12:00pm
Deka-designed, Tidepool-powered auto insulin pump clears FDA
Mar 18, 2024 3:15pm
